Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | MET | P08581 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.31 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.31 |
| ▸ | RRM1 | P23921 | 1/20 | 0.31 |
| ▸ | RRM2B | Q7LG56 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20315037 | 0.74 | MAPT (0.43) | MAPTMETALDH1A1HTT | |
| SCHEMBL20850536 | 0.70 | MAPT (0.36) | MAPTALDH1A1HTT | |
| SCHEMBL21302086 | 0.68 | ADORA2A (0.37) | — | |
| SCHEMBL18408662 | 0.67 | MAPT (0.58) | MAPTALDH1A1HTT | |
| SCHEMBL17030767 | 0.67 | MAPT (0.58) | MAPTALDH1A1HTT | |
| SCHEMBL18133834 | 0.66 | MAPT (0.43) | MAPTMETALDH1A1HTT | |
| SCHEMBL25724221 | 0.64 | MAPT (0.38) | MAPTALDH1A1HTT | |
| SCHEMBL19115364 | 0.63 | MAPT (0.51) | MAPTALDH1A1HTT | |
| SCHEMBL12121763 | 0.62 | MAPT (0.63) | MAPTALDH1A1HTT | |
| SCHEMBL24592345 | 0.62 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230203060-A1 | FUSED TRICYCLIC COMPOUND, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF | GENFLEET THERAPEUTICS (SHANGHAI) INC. (CN) | 2023-06-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230203060-A1 | FUSED TRICYCLIC COMPOUND, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF | KRAS, NRAS, TP53 | MAPT 1542/4885MET 156/4885ALDH1A1 3223/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.